#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12486	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2120	579.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1439	1439	C	702	C	684	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	0	.	n	.	0	T695C	SNP	695	695	T	1053	1053	C	713	C,T,G	685,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1695	1695	A	717	A,G	684,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2329	2329	C	731	C	698	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2403	2403	A	682	A	656	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2955	2955	C	695	C	672	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	0	HET	.	.	.	C2172T	.	2172	2172	C	2530	2530	C	676	C,T	489,166	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22856	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3689	612.4	0	HET	.	.	.	C2501T	.	2501	2501	C	2859	2859	C	698	C,T	492,184	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1380	folP	852	852	100.0	folP.l15.c4.ctg.1	1520	89.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1002	1004	AGC	146;145;146	A;G;C	141;140;140	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3466	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3389	100.7	1	SNP	p	S91F	0	.	.	271	273	TCC	653	655	TCC	119;118;119	T;C;C	115;113;113	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3466	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3389	100.7	1	SNP	p	D95G	0	.	.	283	285	GAC	665	667	GAC	119;120;123	G;A;C	114;112;118	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3466	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3389	100.7	1	SNP	p	D95N	0	.	.	283	285	GAC	665	667	GAC	119;120;123	G;A;C	114;112;118	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1326	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1376	94.6	1	SNP	p	G45D	1	.	.	133	135	GAC	461	463	GAC	146;147;145	G;A;C	144;140;142	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	696	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1010	67.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3674	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2847	126.7	1	SNP	p	D86N	0	.	.	256	258	GAC	539	541	GAC	148;148;151	G;A;C	144;142;149	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3674	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2847	126.7	1	SNP	p	S87W	0	.	.	259	261	AGT	542	544	AGT	154;156;158	A;G;T	147;151;149	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3674	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2847	126.7	1	SNP	p	S87I	0	.	.	259	261	AGT	542	544	AGT	154;156;158	A;G;T	147;151;149	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3674	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2847	126.7	1	SNP	p	S87R	0	.	.	259	261	AGT	542	544	AGT	154;156;158	A;G;T	147;151;149	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3674	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2847	126.7	1	SNP	p	S88P	0	.	.	262	264	TCC	545	547	TCC	159;157;157	T;C,A;C	155;152,1;154	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2934	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2668	108.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1583	1585	GGC	149;148;148	G;G;C	145;146;141	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	A438V	NONSYN	1312	1314	GCA	1683	1685	GTC	163;159;157	G;T;C	159;156;153	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	V444E	NONSYN	1330	1332	GTT	1701	1703	GAA	164;167;168	G;A;A	159;161;158	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	L448V	NONSYN	1342	1344	CTC	1713	1715	GTC	174;172;175	G,C;T;C	164,1;157;162	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	Q458K	NONSYN	1372	1374	CAA	1743	1745	AAA	157;157;159	A;A;A	148;149;151	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	I462V	NONSYN	1384	1386	ATA	1755	1757	GTC	155;155;156	G;T;C	149;144;151	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	F463I	NONSYN	1387	1389	TTC	1758	1760	ATC	153;156;156	A;T;C	144;151;150	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	E465A	NONSYN	1393	1395	GAA	1764	1766	GCC	147;147;148	G,C;C;C	142,1;140;142	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	R469K	NONSYN	1405	1407	CGC	1776	1778	AAA	140;140;140	A;A;A	138;137;137	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	E470K	NONSYN	1408	1410	GAG	1779	1781	AAA	139;138;138	A;A;A	137;134;136	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	N473E	NONSYN	1417	1419	AAT	1788	1790	GAG	133;133;135	G;A;G	130;129;132	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	N513Y	NONSYN	1537	1539	AAC	1908	1910	TAC	121;121;120	T;A;C,A	117;115;113,1	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	G517A	NONSYN	1549	1551	GGT	1920	1922	GCC	130;129;129	G;C,T;C	123;122,1;125	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	A550T	NONSYN	1648	1650	GCA	2019	2021	ACA	93;94;94	A;C;A	87;90;89	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	P553V	NONSYN	1657	1659	CCC	2028	2030	GTC	103;101;104	G;T;C	95;88;97	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	K556Q	NONSYN	1666	1668	AAA	2037	2039	CAA	102;101;103	C;A;A	96;98;98	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	0	.	p	.	0	I557V	NONSYN	1669	1671	ATT	2040	2042	GTT	102;103;102	G;T,C;T	98;96,1;97	.	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1302	1304	GCA	165;165;168	G;C;A	159;156;164	penA.14.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1305	1307	ATC	171;171;171	A;T;C	167;165;165	penA.14.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1317	1319	GTG	167;167;166	G;T;G	164;164;162	penA.14.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1317	1319	GTG	167;167;166	G;T;G	164;164;162	penA.14.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1875	1877	GCG	106;104;104	G;C;G	104;99;102	penA.14.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1875	1877	GCG	106;104;104	G;C;G	104;99;102	penA.14.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1998	2000	GGT	113;112;110	G;G;T	105;105;104	penA.14.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2007	2009	GGC	103;101;100	G;G;C	97;98;95	penA.14.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	539	2826	penA	1749	1749	95.54	penA.l15.c4.ctg.1	2510	110.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2025	2027	CCG	99;100;102	C;C;G	94;95;97	penA.14.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	4494	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3101	143.3	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1610	1612	CTG	162;161;161	C;T;G	154;151;150	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1666	porA	1146	1146	99.83	porA.l15.c30.ctg.1	2101	78.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	674	674	C	111	C	106	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	537	539	GAA	161;158;158	G;A;A	157;154;152	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	S46G	NONSYN	136	138	AGC	561	563	GGC	162;164;168	G;G;C	159;161;161	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	567	569	GGA	173;173;175	G;G;A,C,G	166;165;164,1,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	684	686	GCT	167;166;168	G,A;C;T	155,1;156;155	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	690	692	AGC	162;162;164	A;G;C	155;153;155	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	782	783	CG	184;186	C;G	175;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	785	787	CAG	185;183;184	C;A;G,A	178;178;179,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	789	791	AAA	183;184;186	A;A;A	178;182;184	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	852	854	GAA	179;179;180	G;A;A	175;175;175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	876	878	GCA	193;190;192	G;C,T;A	183;177,1;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	984	986	CGA	185;184;182	C;G;A	177;172;173	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1068	1070	ACT	160;158;158	A;C;T	152;155;153	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1071	1073	CAT	162;162;161	C;A;T	158;160;159	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1077	1079	ATG	163;163;164	A;T;G,C	160;159;158,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1191	1193	GCA	190;186;186	G;C;A	180;178;177	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1194	1196	ACG	186;184;182	A;C;G	173;174;177	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1197	1199	AGG	180;180;179	A;G;G	170;176;173	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1200	1202	GTT	176;177;177	G,A;T;T	171,1;167;172	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1260	1262	GTA	171;169;171	G;T;A	166;164;167	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1299	1301	ACT	183;188;187	A;C;T	173;184;185	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1305	1307	GAT	188;187;186	G;A;T,A	183;181;182,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1308	1310	GAT	192;193;192	G;A,G;T	189;188,1;189	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1314	1316	AAC	193;195;197	A;A;C	190;190;190	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1317	1319	CAC	200;197;198	C;A;C	196;194;194	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	1	SNP	p	G120K	1	.	.	358	360	AAG	782	784	CGG	184;186;184	C;G;G	175;181;178	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	1	SNP	p	A121D	1	.	.	361	363	GAC	785	788	CGC	185;184;183	C;G,A;C	178;179,1;178	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2342	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1615	143.2	1	SNP	p	D121N	0	.	.	361	363	GAC	785	788	CGC	185;184;183	C;G,A;C	178;179,1;178	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8110	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4987	161.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2092	2094	AAT	169;168;171	A;A;T	164;163;165	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	986	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1150	84.6	1	SNP	p	V57M	1	.	.	169	171	ATG	632	634	ATG	199;197;198	A;T;G	194;189;191	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
